| 摘要: |
| 目的探讨分析在治疗糖尿病神经源性膀胱时应用坦索罗辛加依帕司他的疗效及安全性。方法选取2015年1月至2016年12月来我院就诊并确诊为糖尿病神经源性膀胱的患者96例,选取其中48例设为试验组,剩余48例为对照组。试验组采用坦索罗辛结合依帕司他进行治疗,对照组则采用单纯膀胱训练进行治疗,比较两组患者的治疗效果。结果治疗后,两组患者临床症状均有改善,试验组患者改善情况明显优于对照组,差异有统计学意义(P<0.05);两组患者残尿量均下降,试验组患者下降幅度较对照组明显,差异有统计学意义(P<0.05);治疗后,两组患者最大尿流率、最大膀胱容量、膀胱压力指标均有改善,试验组改善较对照组明显,差异有统计学意义(P<0.05),两组中尿白细胞阳性患者占比均下降,试验组患者降幅明显高于对照组,差异有统计学意义(P<0.05)。结论在治疗糖尿病神经源性膀胱时应用坦索罗辛加依帕司他可取得良好效果,且不良反应发生较少,可推广应用。 |
| 关键词: 坦索罗辛 依帕司他 糖尿病神经源性膀胱 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Evaluationof the Efficacy and Safety of the Treatment to Diabetic Neurogenic Bladder with Tamsulosin Combined With Epalrestat |
|
Xu Yan;
|
|
Chengdu 363 Hospital
|
| Abstract: |
| Objective To analysis the efficacy and safety of the treatment to diabetic neurogenic bladder with tamsulosin combined with epalrestat.Methods 96 cases of patients diagnosed with diabetic neurogenic bladder in our hospital from January2015 to December 2016 were averagely divided into two groups,experimental group( n = 48) and control group( n = 48).The experimental group were treated with tamsulosin combined with epalrestat while the control group were treated with bladder training,and then the treatment effect of two groups were compared. Results After treatment,the clinical symptoms of patients in both groups were improved,and the patients in the experimental group were better than the control group( P<0. 05).The proportion of patients with positive urine white blood cell and the residual urine volume of patients in both groups were decreased,and the decreases in the experimental group were bigger than those of control group( P<0. 05).The maximum urinary flow rate,maximum bladder capacity and bladder pressure indicators in both groups were improved,but the improve rate in experimental group was more significant compared with that of control group( P<0. 05).Conclusion In the treatment of diabetic neurogenic bladder,the application of tamsulosin combined with epalrestat could achieve a good result,and had less adverse reactions. Therefore it could be recommended for clinical application |
| Key words: tamsulosin epalrestat diabeticneurogenicbladder |
